PRESS RELEASE

Perspix Biotech pushes tri-specific antibody research

Frankfurt, June 2023

Perspix team members have co-authored a groundbreaking research paper in the well-known Nature Communications journal. The research focuses on the development of a tri-specific T-cell engaging antibody specifically designed to target and eliminate dormant replication-competent provirus in HIV-infected cells.

The research contributes to the objective of finding a functional cure for AIDS and underpins Perspix' ambitions to provide innovative medicines with transforming treatment options across various therapeutic areas. Perspix firmly believes in the immense potential of next-generation tri-specific T-cell engagers. These innovative therapeutics hold promise in transforming disease treatment across various disease areas, particularly in cancer.

Please see here for a full download of the article: Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections | Nature Communications

The Perspix team worked together with esteemed researchers from the National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics, and the University of Lausanne (UNIL).

"The outcome encourages us very much on our way to demonstrate the power of AI and data authority in the development of multi-specific antibodies", says Dr. Joerg Birkenfeld, CSO of Perspix Biotech.

***

For further media information/interview opportunities please contact:

Dr. José Airas

T +49 (0)177 577 9828

E info@perspixbio.tech

Notes to editors:

Perspix is a biotech company specialized in multi-specific antibodies. Perspix creates next-generation biotherapeutics through an end-to-end automated discovery platform. The company aims to radically accelerate the technical development of biological drug modalities with predictive AI, significantly reducing drug development times and costs. The roPROTix platform automatically generates tens of thousands of in-silico designed modalities and analyses them for key functional and biophysical properties in a parallelized approach. This digitally integrated process generates interrelated and multidimensional datasets of unprecedented quantity and quality, which feed directly into ML algorithms that drive the in-silico design engine.

Perspix is headquartered in the FIZ Frankfurt Innovation Center for Biotechnology, Germany